chlorproguanil-dapsone plus artesunate — Competitive Intelligence Brief

chlorproguanil-dapsone plus artesunate (chlorproguanil-dapsone plus artesunate) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antimalarial combination. Area: Infectious Disease.

marketed Antimalarial combination Dihydrofolate reductase (chlorproguanil/dapsone); mitochondrial function (artesunate) Infectious Disease Small molecule

Target snapshot

chlorproguanil-dapsone plus artesunate (chlorproguanil-dapsone plus artesunate) — Centers for Disease Control and Prevention. This combination antimalarial drug works by inhibiting parasite dihydrofolate reductase (via chlorproguanil and dapsone) and disrupting mitochondrial function (via artesunate) to kill Plasmodium parasites through multiple pathways.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
chlorproguanil-dapsone plus artesunate TARGET	chlorproguanil-dapsone plus artesunate	Centers for Disease Control and Prevention	marketed	Antimalarial combination	Dihydrofolate reductase (chlorproguanil/dapsone); mitochondrial function (artesunate)
Chloroquine + Primaquine	Chloroquine + Primaquine	U.S. Army Medical Research and Development Command	marketed	Antimalarial combination	Plasmodium parasite heme metabolism and mitochondrial function
AA(FDC)	AA(FDC)	Medecins Sans Frontieres, Netherlands	marketed	Antimalarial combination	Plasmodium falciparum (multiple mechanisms: artemisinin-based ROS generation and quinoline-based heme polymerization inhibition)
Artemether-lumefantrine combination plus albendazole	Artemether-lumefantrine combination plus albendazole	Navrongo Health Research Centre, Ghana	marketed	Antimalarial combination with anthelmintic	Plasmodium falciparum (multiple mechanisms); Ascaris, Hookworm, Trichuris (tubulin)
Mefloquine- Artesunate	Mefloquine- Artesunate	Centers for Disease Control and Prevention	marketed	Antimalarial combination	Parasite heme detoxification pathway; artemisinin-iron adducts generating reactive oxygen species
IPTp-DP	IPTp-DP	Kenya Medical Research Institute	marketed	Antimalarial combination therapy	Plasmodium falciparum (malaria parasite)
amodiaquine-artesunate versus amodiaquine	amodiaquine-artesunate versus amodiaquine	Charite University, Berlin, Germany	marketed	Antimalarial combination	Malaria parasite heme detoxification pathway; artemisinin-derived endoperoxide bridge

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antimalarial combination class)

1. Centers for Disease Control and Prevention · 4 drugs in this class
2. Armed Forces Research Institute of Medical Sciences, Thailand · 4 drugs in this class
3. London School of Hygiene and Tropical Medicine · 3 drugs in this class
4. Sanofi · 2 drugs in this class
5. Menzies School of Health Research · 2 drugs in this class
6. Fundação de Medicina Tropical Dr. Heitor Vieira Dourado · 1 drug in this class
7. Epicentre · 1 drug in this class
8. Jhpiego · 1 drug in this class
9. Charite University, Berlin, Germany · 1 drug in this class
10. Ifakara Health Institute · 1 drug in this class